"Study to Assess the Efficacy and Safety of Rifaximin Administered BID in the Treatment of Patients With Diarrhea-Associated Irritable Bowel Syndrome", SALIX PHARMACEUTICALS, 6 December 2007 (2007-12-06), XP008140803, Retrieved from the Internet <URL:http://clinicaltrials.gov/ct2/show/NCT00269412> (B1)

WO-A2-2007/064964 (B1)

DUPONT ET AL.: "Rifaximin: A Nonabsorbed Antimicrobial in the Therapy of Travelers' Diarrhea", DIGESTION., vol. 59, no. ISS.6, November 1998 (1998-11-01), pages 708 - 714, XP008140624 (B1)

E. SCARPELLINI ET AL: "High dosage rifaximin for the treatment of small intestinal bacterial overgrowth", ALIMENTARY PHARMACOLOGY & THERAPEUTICS, vol. 25, no. 7, 1 April 2007 (2007-04-01), pages 781 - 786, XP055046220, ISSN: 0269-2813, DOI: 10.1111/j.1365-2036.2007.03259.x (B1)

FRISSORA C L ET AL: "Review article: the role of antibiotics vs. conventional pharmacotherapy in treating symptoms of irritable bowel syndrome.", ALIMENTARY PHARMACOLOGY & THERAPEUTICS 1 JUN 2007, vol. 25, no. 11, 1 June 2007 (2007-06-01), pages 1271 - 1281, XP002718617, ISSN: 0269-2813 (B1)

LAURITANO ET AL.: "Association between Hypothyroidism and Small Intestinal Bacterial Overgrowth", THE JOUMAL OF CLINICAL ENDOCRINOLOGY & METABOLISM., vol. 92, no. ISS.11, November 2007 (2007-11-01), pages 4180 - 4184, XP008140625 (B1)

PIMENTEL ET AL.: "The Effect of a Nonabsorbed Oral Antibiotic (Rifaximin) on the Symptoms of the Irritable Bowel Syndrome", ANNALS OF INTERNAL MEDICINE., vol. 145, no. ISS.8, 17 October 2006 (2006-10-17), pages 557 - 563, XP008140626 (B1)

PIMENTEL MARK ET AL: "A 10-day course of rifaximin, a non-absorbable antibiotic, produces a durable improvement in all symptoms of irritable bowel syndrome: A double-blind randomized controlled study", GASTROENTEROLOGY, vol. 130, no. 4, Suppl. 2, April 2006 (2006-04-01), & DIGESTIVE DISEASE WEEK MEETING/107TH ANNUAL MEETING OF THE AMERICAN-GASTROENTEROLOGICAL-ASSOCIATION; LOS ANGELES, CA, USA; MAY 19 -24, 2006, pages A26, XP002718616, ISSN: 0016-5085 (B1)

RALEIGH, N.C.: "Rifaximin Demonstrates Statistically Significant Improvement in Co-Primary Endpoints in Treatment of Diarrhea-Associated Irritable Bowel Syndrome in Phase IIb Study", September 2007 (2007-09-01), XP002718618, Retrieved from the Internet <URL:http://www.drugs.com/clinical_trials/rifaximin-demonstrates-statistically-significant-improvement-co-primary-endpoints-diarrhea-1851.html?printable=1> [retrieved on 20140113] (B1)

SHAHARA ET AL.: "A Randomized Double-Blind Placebo-Controlled Trial of Rifaximin in Patients with Abdominal Bloating and Flatulence", AMERICAN JOURNAL OF GASTROENTEROLOGY., vol. 101, no. ISS.2, February 2006 (2006-02-01), pages 326 - 333, XP008140619 (B1)

STEFFEN ROBERT ET AL: "Therapy of travelers' diarrhea with rifaximin on various continents.", THE AMERICAN JOURNAL OF GASTROENTEROLOGY MAY 2003, vol. 98, no. 5, May 2003 (2003-05-01), pages 1073 - 1078, XP002718619, ISSN: 0002-9270 (B1)

US-A1- 2005 272 754 (B1)

US-A1- 2007 259 906 (B1)

WO-A2-2006/094737 (B1)

BASS N M: "Review article: the current pharmacological therapies for hepatic encephalopathy", ALIMENTARY PHARMACOLOGY & THERAPEUTICS, BLACKWELL SCIENTIFIC PUBLICATIONS LTD., CAMBRIDGE, GB, vol. 25, no. SUPPL 1, 1 February 2007 (2007-02-01), pages 23 - 31, XP002669397, ISSN: 0269-2813, [retrieved on 20070123], DOI: 10.1111/J.1746-6342.2006.03218.X (B1)